CA2889475A1 - Antibody/drug conjugates and methods of use - Google Patents

Antibody/drug conjugates and methods of use Download PDF

Info

Publication number
CA2889475A1
CA2889475A1 CA2889475A CA2889475A CA2889475A1 CA 2889475 A1 CA2889475 A1 CA 2889475A1 CA 2889475 A CA2889475 A CA 2889475A CA 2889475 A CA2889475 A CA 2889475A CA 2889475 A1 CA2889475 A1 CA 2889475A1
Authority
CA
Canada
Prior art keywords
chain
conjugate
antibody
phor18
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA2889475A
Other languages
English (en)
French (fr)
Inventor
Carola Leuschner
Hector Alila
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
A28 Therapeutics Inc
Original Assignee
Esperance Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Esperance Pharmaceuticals Inc filed Critical Esperance Pharmaceuticals Inc
Publication of CA2889475A1 publication Critical patent/CA2889475A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/95—Fusion polypeptide containing a motif/fusion for degradation (ubiquitin fusions, PEST sequence)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Communicable Diseases (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA2889475A 2012-10-30 2013-10-30 Antibody/drug conjugates and methods of use Pending CA2889475A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261720257P 2012-10-30 2012-10-30
US61/720,257 2012-10-30
PCT/US2013/067621 WO2014070957A1 (en) 2012-10-30 2013-10-30 Antibody/drug conjugates and methods of use

Publications (1)

Publication Number Publication Date
CA2889475A1 true CA2889475A1 (en) 2014-05-08

Family

ID=50622572

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2889475A Pending CA2889475A1 (en) 2012-10-30 2013-10-30 Antibody/drug conjugates and methods of use

Country Status (11)

Country Link
US (5) US9492563B2 (OSRAM)
EP (2) EP4035685A1 (OSRAM)
JP (1) JP6559066B2 (OSRAM)
KR (2) KR20210090298A (OSRAM)
CN (1) CN105121472A (OSRAM)
AU (2) AU2013337926B2 (OSRAM)
BR (1) BR112015009752A2 (OSRAM)
CA (1) CA2889475A1 (OSRAM)
DK (1) DK2914633T3 (OSRAM)
IL (1) IL238323B2 (OSRAM)
WO (1) WO2014070957A1 (OSRAM)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7960139B2 (en) 2007-03-23 2011-06-14 Academia Sinica Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
JP5986745B2 (ja) 2008-07-15 2016-09-06 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ Ｐｔｆｅ様のアルミニウム・コート・ガラススライド上のグリカンアレイおよび関連する方法
US11377485B2 (en) 2009-12-02 2022-07-05 Academia Sinica Methods for modifying human antibodies by glycan engineering
US10087236B2 (en) 2009-12-02 2018-10-02 Academia Sinica Methods for modifying human antibodies by glycan engineering
WO2011130332A1 (en) 2010-04-12 2011-10-20 Academia Sinica Glycan arrays for high throughput screening of viruses
KR101915647B1 (ko) 2010-05-10 2018-11-06 아카데미아 시니카 항-인플루엔자 활성을 가진 자나미비르 포스포네이트 동족체 및 인플루엔자 바이러스의 오셀타미비르 감수성을 확인하는 방법
US10130714B2 (en) 2012-04-14 2018-11-20 Academia Sinica Enhanced anti-influenza agents conjugated with anti-inflammatory activity
JP6302909B2 (ja) 2012-08-18 2018-03-28 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ シアリダーゼの同定および画像化のための細胞透過性プローブ
AU2013305827A1 (en) 2012-08-21 2015-03-05 Academia Sinica Benzocyclooctyne compounds and uses thereof
IL238323B2 (en) 2012-10-30 2023-11-01 Esperance Pharmaceuticals Inc Antibody/drug conjugates and methods of use
EP3013365B1 (en) 2013-06-26 2019-06-05 Academia Sinica Rm2 antigens and use thereof
WO2014210564A1 (en) 2013-06-27 2014-12-31 Academia Sinica Glycan conjugates and use thereof
CN105682666B (zh) 2013-09-06 2021-06-01 中央研究院 使用醣脂激活人类iNKT细胞
US10150818B2 (en) 2014-01-16 2018-12-11 Academia Sinica Compositions and methods for treatment and detection of cancers
JP2017507118A (ja) 2014-01-16 2017-03-16 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ がんの処置および検出のための組成物および方法
CN106415244B (zh) 2014-03-27 2020-04-24 中央研究院 反应性标记化合物及其用途
TWI679020B (zh) 2014-05-27 2019-12-11 中央研究院 抗ｈｅｒ２醣抗體及其用途
US20150344585A1 (en) 2014-05-27 2015-12-03 Academia Sinica Anti-cd20 glycoantibodies and uses thereof
US10118969B2 (en) 2014-05-27 2018-11-06 Academia Sinica Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
TWI717319B (zh) 2014-05-27 2021-02-01 中央研究院 得自類桿菌屬之岩藻糖苷酶及其用途
TWI732738B (zh) 2014-05-28 2021-07-11 中央研究院 抗TNF-α醣抗體及其用途
TWI745275B (zh) 2014-09-08 2021-11-11 中央研究院 使用醣脂激活人類ｉＮＫＴ細胞
CN107001469A (zh) * 2014-09-12 2017-08-01 比奥根Ma公司 人源化抗‑αvβ5抗体及其用途
ES2921208T3 (es) 2014-12-08 2022-08-19 Us Health Receptores de antígeno quimérico anti-CD70
US10495645B2 (en) 2015-01-16 2019-12-03 Academia Sinica Cancer markers and methods of use thereof
US9975965B2 (en) 2015-01-16 2018-05-22 Academia Sinica Compositions and methods for treatment and detection of cancers
CA2972072A1 (en) 2015-01-24 2016-07-28 Academia Sinica Novel glycan conjugates and methods of use thereof
CN107921146A (zh) * 2015-06-23 2018-04-17 拜耳医药股份有限公司 纺锤体驱动蛋白(ksp)抑制剂与抗‑cd123的抗体的抗体药物缀合物(adc)
JP6990650B2 (ja) * 2015-09-17 2022-03-04 ザ スクリプス リサーチ インスティテュート 二重可変ドメインイムノコンジュゲートおよびその用途
EP4074731A1 (en) * 2015-11-04 2022-10-19 City of Hope Chimeric antigen receptors targeting her2
AU2017213661B2 (en) * 2016-02-05 2022-06-02 City Of Hope Administration of engineered T cells for treatment of cancers in the central nervous system
TW201808978A (zh) 2016-03-08 2018-03-16 中央研究院 N-聚醣及其陣列之模組化合成方法
CA3032320A1 (en) * 2016-08-03 2018-02-08 H. Lee Moffitt Cancer Center And Research Institute, Inc. Tlr9 targeted therapeutics
CN106248971B (zh) * 2016-08-19 2017-10-03 合肥瀚科迈博生物技术有限公司 用于检测人血清中her2含量的elisa试剂盒、使用方法及用途
EP3500594A4 (en) 2016-08-22 2020-03-11 Cho Pharma Inc. ANTIBODIES, BINDING FRAGMENTS AND METHOD FOR USE
US20230182041A1 (en) * 2018-04-25 2023-06-15 Medimmune, Llc Purification of antibodies
CN114555641A (zh) * 2019-07-02 2022-05-27 泰利克斯国际有限公司 对新生儿Fc受体具有减少的亲和力的用于结合PSMA的抗体
CN111100204B (zh) * 2019-11-26 2022-03-11 山东立菲生物产业有限公司 靶向cd20的抗体、其制备方法和应用
AU2021212193A1 (en) * 2020-01-31 2022-09-08 Celgene Corporation Anti-CD30 antibody-drug conjugates and their use for the treatment of non-Hodgkin lymphoma
CN115768455A (zh) * 2020-03-26 2023-03-07 A28治疗公司 溶解结构域融合构建体、检查点抑制剂、以及制造和使用它们的方法
US11782685B2 (en) 2020-06-17 2023-10-10 Bank Of America Corporation Software code vectorization converter
US11573775B2 (en) 2020-06-17 2023-02-07 Bank Of America Corporation Software code converter for resolving redundancy during code development
US11347500B2 (en) 2020-06-17 2022-05-31 Bank Of America Corporation Software code converter for resolving conflicts during code development
US11617767B2 (en) 2020-11-20 2023-04-04 Simcere Innovation, Inc. Armed dual CAR-T compositions and methods for cancer immunotherapy
CN113326087B (zh) * 2021-05-19 2023-01-24 翱捷科技股份有限公司 一种lvgl上的中文字库处理方法及装置
TW202320857A (zh) 2021-07-06 2023-06-01 美商普方生物製藥美國公司 連接子、藥物連接子及其結合物及其使用方法
EP4460564A2 (en) * 2022-01-08 2024-11-13 Carogen Corporation Multi-antigen therapeutic vaccines to treat or prevent chronic hepatitis b virus infection
JP2025528832A (ja) * 2022-08-15 2025-09-02 ナヴロジェン インコーポレイテッド 腫瘍免疫抑制性ＩＣＡＭ－１／ＣＤ５４に対し抵抗性のＦｃ改変モノクローナル抗体
CN116514998B (zh) * 2023-05-12 2023-09-15 再少年(北京)生物科技有限公司 一种嵌合抗原受体、嵌合抗原受体-自然杀伤细胞及其在制备抗肿瘤药物中的应用
CN116593716B (zh) * 2023-07-11 2023-10-13 军科正源（北京）药物研究有限责任公司 检测抗PEG-rhGH中和抗体的方法
WO2025131119A1 (en) * 2023-12-22 2025-06-26 Everest Medicines (China) Co., Ltd. Cancer vaccines and uses thereof
WO2025167838A1 (en) * 2024-02-08 2025-08-14 Suzhou Bioreinno Biotechnology Limited Company Antibodies, antibody-drug conjugates, and producing methods thereof
CN119331056B (zh) * 2024-09-25 2025-07-22 青岛大学 一种[Tyr3]Octreotate-D-构型溶瘤肽缀合物及其荧光探针的制备方法和应用

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5273876A (en) 1987-06-26 1993-12-28 Syntro Corporation Recombinant human cytomegalovirus containing foreign gene
US5861478A (en) 1987-07-06 1999-01-19 Helix Biomedix, Inc. Lytic peptides
EP0383770B1 (en) 1987-07-06 1995-09-13 Louisiana State University and Agricultural and Mechanical College Inhibition of eucaryotic pathogens and neoplasms with lytic peptides
CA1327311C (en) 1987-07-06 1994-03-01 Jesse M. Jaynes Therapeutic antimicrobial polypeptides, their use and methods for preparation
EP0448650A4 (en) 1989-02-01 1992-05-13 The General Hospital Corporation Herpes simplex virus type i expression vector
US5459237A (en) 1990-02-08 1995-10-17 Magainin Pharmaceuticals Inc. Peptide compositions and uses therefor
US5792831A (en) 1990-02-08 1998-08-11 Magainin Pharmaceuticals Inc. Analogues of magainin peptides containing D-amino acids
WO1991012015A1 (en) 1990-02-08 1991-08-22 Magainin Sciences Inc. Biologically active amphiphilic peptides and method of inhibiting growth of target cells, virus or virally-infected cell
GB9105383D0 (en) 1991-03-14 1991-05-01 Immunology Ltd An immunotherapeutic for cervical cancer
EP0590044A4 (en) 1991-06-12 1996-06-12 Magainin Pharma Composition and treatment with biologically active peptides having c-terminal substitutions
EP0940468A1 (en) 1991-06-14 1999-09-08 Genentech, Inc. Humanized antibody variable domain
AU3236293A (en) 1991-12-09 1993-07-19 Magainin Pharmaceuticals, Inc. Composition and treatment with biologically active peptides and chelating agents
WO1993021319A1 (en) * 1992-04-08 1993-10-28 Cetus Oncology Corporation HUMANIZED C-erbB-2 SPECIFIC ANTIBODIES
US6348445B1 (en) 1992-06-01 2002-02-19 Magainin Pharmaceuticals, Inc. Biologically active peptides with reduced toxicity in animals and a method for preparing same
WO1993024138A1 (en) 1992-06-01 1993-12-09 Magainin Pharmaceuticals, Inc. Biologically active peptides having n-terminal substitutions
JPH08504172A (ja) 1992-06-30 1996-05-07 オンコロジクス，インコーポレイティド 抗−ｅｒｂＢ−２モノクロナール抗体の組み合わせ物及び使用方法
AU5081193A (en) 1992-08-31 1994-03-29 Magainin Pharmaceuticals, Inc. Treatment of gynecological malignancies with biologically active peptides
WO1994012629A1 (en) 1992-12-02 1994-06-09 Baylor College Of Medicine Episomal vectors for gene therapy
WO1994012206A1 (en) 1992-12-03 1994-06-09 Magainin Pharmaceuticals, Inc. Treatment of dermatological malignancies with biologically active peptides
AU5741794A (en) 1992-12-07 1994-07-04 Magainin Pharmaceuticals, Inc. Treatment of septic shock with conjugated biologically active peptides
WO1994019369A1 (en) 1993-02-26 1994-09-01 Magainin Pharmaceuticals, Inc. Treatment of cancerous growths with biologically active peptides and protease inhibitors
EP0753071A1 (en) 1993-04-28 1997-01-15 Worcester Foundation For Experimental Biology Cell-targeted lytic pore-forming agents
US5773413A (en) 1993-06-04 1998-06-30 Demeter Biotechnologies, Ltd. Method of combating mammalian neoplasias, and lytic peptides therefor
WO1994028921A1 (en) 1993-06-04 1994-12-22 Demeter Biotechnologies, Ltd. Method of treating pulmonary disease states with non-naturally occurring amphipathic peptides
US5561107A (en) 1993-06-04 1996-10-01 Demeter Biotechnologies, Ltd. Method of enhancing wound healing by stimulating fibroblast and keratinocyte growth in vivo, utilizing amphipathic peptides
US5955573A (en) 1993-06-04 1999-09-21 Demegen, Inc. Ubiquitin-lytic peptide fusion gene constructs, protein products deriving therefrom, and methods of making and using same
US5968904A (en) 1993-06-04 1999-10-19 Demegen, Inc. Modified arginine containing lytic peptides and method of making the same by glyoxylation
WO1995013085A1 (en) 1993-11-08 1995-05-18 Demeter Biotechnologies Ltd. Methylated lysine-rich lytic peptides and method of making same by reductive alkylation
WO1995013377A1 (en) 1993-11-12 1995-05-18 Case Western Reserve University Episomal expression vector for human gene therapy
CA2117668C (en) 1994-03-09 2005-08-09 Izumu Saito Recombinant adenovirus and process for producing the same
US5789542A (en) 1994-04-22 1998-08-04 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Amphipathic peptides
US5604090A (en) 1994-06-06 1997-02-18 Fred Hutchinson Cancer Research Center Method for increasing transduction of cells by adeno-associated virus vectors
IL114697A0 (en) 1994-07-22 1995-11-27 Demeter Biotech Ltd Polypeptides comprising ubiquitin-lytic peptide fusion protein products deriving therefrom their preparation and use
US5693508A (en) 1994-11-08 1997-12-02 Chang; Lung-Ji Retroviral expression vectors containing MoMLV/CMV-IE/HIV-TAR chimeric long terminal repeats
JP3770333B2 (ja) 1995-03-15 2006-04-26 大日本住友製薬株式会社 組換えｄｎａウイルスおよびその製造方法
US5783186A (en) 1995-12-05 1998-07-21 Amgen Inc. Antibody-induced apoptosis
AUPN861496A0 (en) * 1996-03-13 1996-04-04 Commonwealth Scientific And Industrial Research Organisation Lytic peptides
US5712379A (en) * 1996-06-07 1998-01-27 California Institute Of Technology Method and compositions for controlling gene expression
JP2001501620A (ja) 1996-10-04 2001-02-06 デメジェン インコーポレイテッド 免疫不全ウイルス感染の治療方法
WO2000053755A2 (en) 1999-03-08 2000-09-14 Genentech, Inc. Compositions and methods for the treatment of tumor
US6566334B1 (en) 1997-02-06 2003-05-20 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Short amphipathic peptides with activity against bacteria and intracellular pathogens
AU6587998A (en) 1997-03-27 1998-10-20 Demeter Biotechnologies, Ltd. Ligand/lytic peptide compositions and methods of use
US6635740B1 (en) 1997-03-27 2003-10-21 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Ligand/lytic peptide compositions and methods of use
AU8300598A (en) 1997-07-15 1999-02-10 Magainin Pharmaceuticals, Inc. Biologically active peptides with reduced toxicity in animals and a method for preparing same
US6680058B1 (en) 1997-09-03 2004-01-20 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Compositions and methods for contraception in or sterilization of mammals
US6461813B2 (en) 1998-09-21 2002-10-08 Rigel Pharmaceuticals, Inc. Multiparameter FACS assays to detect alterations in cell cycle regulation
US6656906B1 (en) 1998-05-20 2003-12-02 Trimeris, Inc. Hybrid polypeptides with enhanced pharmacokinetic properties
GB0005702D0 (en) 2000-03-09 2000-05-03 Alpharma As Method
SK3752002A3 (en) 1999-09-23 2003-06-03 Zentaris Ag Method for the therapeutic management of extrauterine proliferation of endometrial tissue, chronic pelvic pain and fallopian tube obstruction
ES2312435T3 (es) 2000-03-14 2009-03-01 Aeterna Zentaris Gmbh Antagonistas de lhrh, su preparacion y su uso como medicamentos.
US7097840B2 (en) 2000-03-16 2006-08-29 Genentech, Inc. Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
US6875744B2 (en) 2001-03-28 2005-04-05 Helix Biomedix, Inc. Short bioactive peptides
ES2281551T3 (es) 2001-11-15 2007-10-01 Pantarhei Bioscience B.V. Metodo de prevencion o tratamiento de enfermedades ginecologicas benignas.
US7435797B2 (en) 2002-04-10 2008-10-14 Genentech, Inc. Anti-HER2 antibody variants
JP4472998B2 (ja) 2002-04-22 2010-06-02 ダウ グローバル テクノロジーズ インコーポレイティド 低コストのペプチド製造
MXPA05003318A (es) 2002-09-27 2005-09-12 Zentaris Gmbh Forma de administracion para peptidos farmaceuticamente activos con liberacion sostenida y metodo para la produccion de los mismos.
KR100932340B1 (ko) * 2002-10-17 2009-12-16 젠맵 에이/에스 Ｃｄ20에 대한 인간 모노클로날 항체
US20040167919A1 (en) 2003-02-24 2004-08-26 David Sterling Methods for selectable display of parts of a document on a computer monitor
US7091185B2 (en) 2003-02-24 2006-08-15 Dow Global Technologies Inc. Periodic antimicrobial peptides
EP1599499A2 (en) 2003-02-24 2005-11-30 Dow Global Technologies Inc. Periodic antimicrobial peptides
GB0307777D0 (en) 2003-04-04 2003-05-07 Medical Res Council Conjugate compounds
NO20031818D0 (no) 2003-04-23 2003-04-23 Uni I Tromsoe Fremgangsmåte av bioaktiv peptid forberedelse
GB0320806D0 (en) 2003-09-05 2003-10-08 Astrazeneca Ab Therapeutic treatment
WO2005062881A2 (en) 2003-12-24 2005-07-14 Transgenrx, Inc. Gene therapy using transposon-based vectors
EP1740946B1 (en) * 2004-04-20 2013-11-06 Genmab A/S Human monoclonal antibodies against cd20
KR20110050567A (ko) * 2004-07-22 2011-05-13 제넨테크, 인크. Ｈｅｒ２ 항체 조성물
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
GB0506759D0 (en) 2005-04-02 2005-05-11 Medical Res Council Combination treatment methods
WO2006130834A2 (en) 2005-05-31 2006-12-07 Board Of Regents, The University Of Texas System IGGl ANTIBODIES WITH MUTATED FC PORTION FOR INCREASED BINDING TO FCRN RECEPTOR AND USES THEREOF
WO2007115033A2 (en) 2006-03-31 2007-10-11 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Layered nanoparticles for sustained release of small molecules
WO2008016633A2 (en) * 2006-08-02 2008-02-07 Ariad Gene Therapeutics, Inc. Combination therapy
US7288622B1 (en) 2006-09-19 2007-10-30 Issar Pharmaceuticals Pvt Ltd Composition for treatment of burns and wounds
US7803755B2 (en) 2006-12-21 2010-09-28 Jesse Jaynes Molecules for the treatment and prevention of fungal diseases
AU2009206212B2 (en) 2008-01-24 2014-01-16 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Lytic domain fusion constructs and methods of making and using same
CN104524590B (zh) * 2008-04-30 2019-06-21 伊缪诺金公司 交联剂和它们的用途
US20110124564A1 (en) 2009-08-25 2011-05-26 Esperance Pharmaceuticals, Inc. Nucleolin-binding peptides, nucleolin- binding lytic peptides, fusion constructs and methods of making and using same
CA2780713A1 (en) * 2009-09-03 2011-03-10 Vancouver Biotech Ltd. Monoclonal antibodies against gonadotropin-releasing hormone receptor
US10093961B2 (en) 2009-12-22 2018-10-09 Esperance Pharmaceuticals Methods for diagnosis of and predicting treatment efficacy of hormone receptor expressing tumors, cancers and neoplasias
WO2011137245A2 (en) * 2010-04-30 2011-11-03 Esperance Pharmaceuticals, Inc. Lytic-peptide-her2/neu (human epidermal growth factor receptor 2) ligand conjugates and methods of use
WO2012050892A2 (en) 2010-09-29 2012-04-19 Esperance Pharmaceuticals, Inc. Methods for stimulating, increasing or enhancing killing of a cell that expresses luteinizing hormone releasing hormone (lhrh) receptors
IL238323B2 (en) 2012-10-30 2023-11-01 Esperance Pharmaceuticals Inc Antibody/drug conjugates and methods of use
JP2016506373A (ja) 2012-11-15 2016-03-03 エスペランス ファーマシューティカルズ， インコーポレイテッド 卵胞刺激ホルモン（ｆｓｈ）／溶解ドメイン融合コンストラクト及びその作製及び使用の方法

Also Published As

Publication number Publication date
EP2914633A1 (en) 2015-09-09
IL238323B1 (en) 2023-07-01
KR20210090298A (ko) 2021-07-19
AU2018201996A1 (en) 2018-04-12
US20220048951A1 (en) 2022-02-17
IL238323A0 (en) 2015-06-30
JP2016501839A (ja) 2016-01-21
CN105121472A (zh) 2015-12-02
US20140127241A1 (en) 2014-05-08
KR102460297B1 (ko) 2022-10-28
EP4035685A1 (en) 2022-08-03
KR20150095637A (ko) 2015-08-21
BR112015009752A2 (pt) 2017-07-11
EP2914633B1 (en) 2021-12-08
US20170121370A1 (en) 2017-05-04
US10233214B2 (en) 2019-03-19
AU2013337926A1 (en) 2015-05-07
AU2018201996B2 (en) 2019-06-20
IL238323B2 (en) 2023-11-01
AU2013337926B2 (en) 2017-12-21
HK1214828A1 (zh) 2016-08-05
JP6559066B2 (ja) 2019-08-14
DK2914633T3 (da) 2022-03-14
US20190367558A1 (en) 2019-12-05
US20250092092A1 (en) 2025-03-20
EP2914633A4 (en) 2016-07-06
WO2014070957A1 (en) 2014-05-08
US9492563B2 (en) 2016-11-15

Similar Documents

Publication Publication Date Title
US20250092092A1 (en) Antibody/drug conjugates and methods of use
AU2020291012B2 (en) Novel IL-15 prodrugs and methods of use thereof
US20220289822A1 (en) Novel il-21 prodrugs and methods of use thereof
US10729740B2 (en) Lytic-peptide-Her2/neu (Human Epidermal growth factor Receptor 2) ligand conjugates and methods of use
KR20170132793A (ko) Afp 펩티드/mhc 복합체를 표적화하는 구축물 및 그의 용도
CN106279418A (zh) Bcma（cd269/tnfrsf17）结合蛋白
AU2022297538A1 (en) Extended-release immune cell engaging proteins and methods of treatment
TW202216762A (zh) Tgfbr2-ecd突變體及包含其的融合蛋白與應用
WO2024119193A2 (en) Mutant il-2 polypeptides and il-2 prodrugs
CN114286825A (zh) 嵌合抗原受体t细胞及其用途
CN121100003A (zh) 修饰的抗体、其抗体片段和抗体药物偶联物
HK40078723A (en) Antibody/drug conjugates and methods of use
HK1214828B (en) Antibody/drug conjugates and methods of use
AU2023403270A1 (en) Mutant il-2 polypeptides and il-2 prodrugs
AU2021282817A1 (en) Bispecific antibody or antigen-binding fragment thereof, and preparation method therefor

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20181016

EEER Examination request

Effective date: 20181016

EEER Examination request

Effective date: 20181016

EEER Examination request

Effective date: 20181016

EEER Examination request

Effective date: 20181016

EEER Examination request

Effective date: 20181016

EEER Examination request

Effective date: 20181016

EEER Examination request

Effective date: 20181016

EEER Examination request

Effective date: 20181016

EEER Examination request

Effective date: 20181016